It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Prostaglandin induced signalling is involved in different cancers. As previously described, the EP3 receptor expression decreases with increasing stage of cervical intraepithelial lesions (CIN). In addition, in cervical cancer EP3 is an independent prognosticator for overall survival and correlates with FIGO stages. Currently the role of Prostaglandin 2 receptor 2 (EP2) in CIN is unknown. The aim of this study was to analyse the expression of EP2 for potential prognostic value for patients with cervical dysplasia. EP2 expression was analysed by immunohistochemistry in 33 patient samples (CIN1–3) using the immune-reactivity scoring system (IRS). Expression levels were correlated with clinical outcome to analyse prognostic relevance in patients with CIN2. Data analysis was performed using non parametric Kruskal–Wallis and Spearman rank sum test. Cytoplasmic expression levels of EP2 correlated significantly (p < 0.001) with different grades of cervical dysplasia. Median EP2-IRS in CIN1 was 2 (n = 8), 3 in CIN2 (n = 9) and 6 in CIN3 (n = 16). Comparing regressive (n = 3, median IRS = 2) to progressive (n = 6, median IRS = 4) CIN2 cases the median IRS differed significantly (p = 0.017). Staining intensity (p = 0.009) and IRS (p = 0.005) of EP2 and EP3 correlate inversely. EP2 expression level significantly increases with higher grade of CIN and could qualify as a potential prognostic marker for the regressive or progressive course in CIN2 lesions. These findings emphasize the significant role of PGE2 signalling in CIN and could help to identify targets for future therapies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 LMU Munich, Department of Pathology, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
2 University Hospital, LMU Munich, Department of Obstetrics and Gynaecology, Munich, Germany (GRID:grid.5252.0)
3 LMU Munich, Department of Pathology, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); University Hospital, LMU Munich, Department of Obstetrics and Gynaecology, Munich, Germany (GRID:grid.5252.0); University Hospital Augsburg, Department of Obstetrics and Gynaecology, Augsburg, Germany (GRID:grid.419801.5) (ISNI:0000 0000 9312 0220)
4 LMU Munich, Department of Pathology, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); University Hospital, LMU Munich, Department of Obstetrics and Gynaecology, Munich, Germany (GRID:grid.5252.0)
5 LMU Munich, Department of Obstetrics and Gynaecology, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)